The Real Cost of Childhood Cancer Treatment: Targeted Therapy Prices Explained

For relapsed ALL, inotuzumab and blinatumomab are both available. Inotuzumab is the more affordable option since it only requires day-care admission, roughly 10,000 to 12,000 US dollars per cycle (day 1, 8 and 15), and some manufacturers offer buy-one-get-one support schemes. Blinatumomab is costlier, at 30 to 40 lakh Indian rupees, because it requires 28 days of hospitalization with continuous infusion, so it is used far less often for international patients. Anti-GD2 therapy (dinutuximab) for neuroblastoma runs around 70 to 80 lakh rupees, though the price has been coming down.

Dr. Danewa put inotuzumab at roughly 10,000 to 12,000 US dollars per cycle, noted that the 70 to 80 lakh rupee cost of dinutuximab converts to about 80,000 US dollars, and priced brentuximab plus nivolumab immunotherapy for Hodgkin lymphoma in a similar range to inotuzumab, around 12,000 to 15,000 US dollars.

Dr. Danewa explained that upfront bone marrow transplant has no role in most pediatric leukemia. It is reserved for cases without morphological remission (blasts above 10% at the end of induction), for hypodiploidy (fewer than 44 chromosomes), or for relapse. For benign conditions, the leading indication, especially in Africa, is sickle cell disease, where earlier transplant, ideally before age 12 and before pain crises, stroke or chest syndrome accumulate, gives a better outcome. He described three transplant types: matched sibling, matched unrelated donor via registry, and haploidentical transplant from a parent, with haploidentical success running around 70 to 80% depending on the underlying disease.

Yes. Dr. Danewa confirmed bone marrow transplant is a cure for sickle cell disease, and that outcomes are best the earlier it is done, since delay allows organ damage and comorbidities to accumulate and lowers the chance of success.

In relapsed or refractory leukemia, where prior treatment options offered only a 5 to 10% chance of success, both Western data and four to five years of follow-up on India's own indigenous CAR T-cell programs are now showing 50 to 60% success.

As long as a case stays surgical, cost stays manageable. The moment treatment needs an advanced cancer drug, cost rises sharply, and the single biggest driver of that rise is how pharmaceutical manufacturers price the medicine itself, not the hospital care surrounding it.

Blinatumomab costs roughly 30 to 40 lakh rupees and requires 28 days of hospitalization with continuous infusion, so the cost and logistics together mean it is rarely offered to international patients.

Some manufacturers offer buy-one-get-one support schemes for inotuzumab, making it more accessible than other targeted therapies for the same indication.

India is delivering outcomes considered close to comparable with Western centers, at roughly a tenth of the cost, a gap expected to keep narrowing over the coming years as indigenous drug development continues.